Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 3

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Sarcoma 1CNS 1

Conditions

Prostatic Neoplasms 1Pain 1Oligodendroglioma 1Neoplasm Metastasis 1Gliosarcoma 1Glioma 1Glioblastoma 1Carcinoma, Renal Cell 1Brain Neoplasms 1Astrocytoma 1

Interventions

Specimen Handling 180Cyclophosphamide 161Magnetic Resonance Spectroscopy 153Biopsy 128Radiotherapy 109Cisplatin 109Bevacizumab 107Carboplatin 101Doxorubicin 96Paclitaxel 94Etoposide 87Filgrastim 81aldesleukin 78Gemcitabine 73Vincristine 72Fluorouracil 72Leucovorin 62fludarabine phosphate 58Docetaxel 58Bortezomib 54Sorafenib 53Cytarabine 51Methotrexate 50Taxes 49Immunoglobulin G 49Disulfides 49Rituximab 48Oxaliplatin 48sargramostim 47Prednisone 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × NIH × tandutinib × Clear all
NCT00408902 2017-11-22

Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Completed
10 enrolled 6 charts
Genitourinary

Carcinoma, Renal Cell

NCT00667394 2015-11-05

Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
42 enrolled 11 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT00390468 2014-05-28

Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases

National Cancer Institute (NCI)

Phase 2 Completed
18 enrolled 5 charts
Genitourinary

Neoplasm Metastasis, Pain, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡